by 
Aortic stenosis refers to the narrowing of the aortic valve opening, which impedes the blood flow from the left ventricle into the aorta. Symptoms of aortic stenosis include chest pain, shortness of breath, fainting, and fatigue. Aortic stenosis occurs when the aortic valve thickens and stiffens over time due to the build-up of calcium on the valves. If left untreated, it can cause damage to the heart and eventually lead to heart failure. The global aortic stenosis market has been growing rapidly owing to the rising prevalence of aortic stenosis and the associated mortality. According to recent estimates, over 5 million Americans suffer from some form of valvular heart disease, with aortic stenosis being one of the most common conditions affecting over 200,000 new patients every year in the US alone. The growing geriatric population is a major driver of the rising prevalence as aortic stenosis is more common in older individuals.
The global Aortic Stenosis Market is estimated to be valued at US$ 8.33 Bn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Key Trends
One of the major trends fueling the growth of the aortic stenosis market is increasing adoption of transcatheter aortic valve replacement (TAVR). TAVR has revolutionized the treatment of aortic stenosis by providing a minimally invasive alternative to open-heart surgery. Some of the key advantages of TAVR over surgical aortic valve replacement include lower risks of mortality and morbidity, faster recovery time and reduced hospital stay. With improving technology, TAVR is now preferred in high-risk as well as intermediate-risk patients, which is driving its uptake substantially. According to estimates, over 300,000 TAVR procedures are performed annually worldwide currently. This rapid adoption of TAVR is expected to continue over the forecast period, significantly contributing to the growth of the aortic stenosis market.
Porter’s Analysis
Threat of new entrants: Low barriers to entry in terms of capital requirements and technology. However, established players dominate the market making it difficult for new players.
Bargaining power of buyers: Multiple treatment options available giving buyers adequate choice and power.
Bargaining power of suppliers: Suppliers have moderate to high bargaining due to unique technologies and patents controlling the market.
Threat of new substitutes: Low threat currently due to lack of effective substitutes for Transcatheter Aortic Valve Replacement (TAVR).
Competitive rivalry: High rivalry among major players trying to gain revenue share through continuous innovations in devices and therapies for aortic stenosis.
Key Takeaways
The global Aortic Stenosis Market is expected to witness high growth. The market in North America holds the largest share currently due to wide adoption of transcatheter aortic valve replacement procedures and supportive reimbursement policies in the region. Key players operating in the Aortic Stenosis are Edwards Lifesciences Corporation, Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, CryoLife, Inc. Edwards Lifesciences Corporation is the leader in the transcatheter heart valves market with sustainable growth through product enhancements and geographic expansions.
Regional analysis:
North America dominates the aortic stenosis market currently with the highest procedure volumes. The Asia Pacific region is expected to grow at the fastest pace during the forecast period due to rising incidences of rheumatic heart disease and growing medical tourism in countries such as India and China providing growth opportunities.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
